Table 1.
Characteristics of Patients in the United Kingdom Collaborative HIV Cohort Study Who Were Exposed to Tenofovir Disoproxil Fumarate (TDF) for ≥6 Months
| Characteristic | Value |
|
|---|---|---|
| Male sex | 10 550 | (81.1) |
| Ethnicity | ||
| White | 8300 | (63.8) |
| Black | 3026 | (23.3) |
| Other/unknown | 1681 | (12.9) |
| Route of HIV exposure | ||
| Homosexual/bisexual sex | 8236 | (63.3) |
| Heterosexual sex | 3713 | (28.6) |
| IDU | 356 | (2.7) |
| Other/unknown | 702 | (5.4) |
| Calendar year | ||
| 1999–2003 | 2482 | (19.1) |
| 2004–2007 | 3992 | (30.7) |
| 2008–2010 | 6533 | (50.2) |
| Previous exposure to TDF | 603 | (4.6) |
| ART naive | 4466 | (34.4) |
| ARV class | ||
| PI based (no ATZ) | 2690 | (20.7) |
| PI based (with ATZ) | 1329 | (10.2) |
| NNRTI based | 7098 | (54.6) |
| Other | 1890 | (14.5) |
| Previous AIDS-defining event | 3053 | (23.5) |
| HBV status | ||
| Negative | 8412 | (64.7) |
| Positive | 599 | (4.6) |
| Not tested | 3996 | (30.7) |
| HCV status | ||
| Negative | 8619 | (66.3) |
| Positive | 730 | (5.6) |
| Not tested | 3658 | (28.1) |
| eGFR | ||
| <60 mL/min/1.73 m2 | 166 | (1.4) |
| 60–74 mL/min/1.73 m2 | 985 | (8.5) |
| 75–89 mL/min/1.73 m2 | 2572 | (22.1) |
| ≥90 mL/min/1.73 m2 | 7898 | (68.0) |
| Age, y | 40 | (34–46) |
| CD4+ T-cell count, cells/mm3 | 303 | (190–482) |
| HIV load, log10 copies/mL | 2.9 | (1.7–4.7) |
Data are no. (%) of patients or median value (interquartile range) and were recorded at the start of TDF therapy.
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; ATZ, atazanavir; eGFR, estimate glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.
a Data are for 11 621 patients with eGFR measure available in the 6 months preceding TDF therapy.